Funding profile · Healthcare AI agents
Hippocratic AI
About $404 million announced across six financings, a $3.5 billion valuation in November 2025, a January 2026 acquisition, and no Form D anywhere in EDGAR under the company’s name.
$404MTotal raised through the Series C, company-reported (Nov 2025)
$3.5BSeries C valuation, company-reported
7xValuation step-up, $500M (Mar 2024) to $3.5B (Nov 2025)
0Form D notices found in EDGAR under the Hippocratic name
Data as of November 11, 2026. Company-reported figures are labeled. Valuations are as announced and are not confirmed by any filing.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| May 2023 | Seed | $50M | Co-led by General Catalyst and Andreessen Horowitz | Company release |
| Jul 2023 | Seed extension | $15M | Not itemized | Independent |
| Mar 2024 | Series A | $53M at a $500M valuation | Co-led by Premji Invest and General Catalyst; SV Angel, Memorial Hermann, Andreessen Horowitz, Cincinnati Children’s, WellSpan Health, Universal Health Services | Company release |
| 2024 | Series A follow-on | $17M | Nvidia (NVentures); trackers also list Greycroft and 7wireVentures | Independent |
| Jan 2025 | Series B | $141M at a $1.64B valuation | Led by Kleiner Perkins; Andreessen Horowitz, General Catalyst, Premji, Nvidia, SV Angel, UHS and WellSpan at or above pro rata | Company release |
| Nov 2025 | Series C | $126M at a $3.5B valuation | Led by Avenir Growth; CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest and health system investors | Company release |
| Jan 2026 | Acquisition of Grove AI | Terms not disclosed | Hippocratic AI as buyer | Acquirer-stated |
| 2026 | Unannounced capital | About $40M implied | Not disclosed | Unreconciled |
What the filings show
Hippocratic AI · Form D search · checked Nov 11, 2026
- Result
- No Form D located for any round
- Searched
- EDGAR full-text search of Form D filings for “Hippocratic AI” and “Hippocratic”, plus the EDGAR company index
- Name collision
- The only EDGAR entity with the name is Hippocratic Financial Advisors, LLC (CIK 0002055803), an investment adviser that files 13F holdings reports. It is unrelated.
- Implication
- None of the roughly $400 million announced appears on the SEC record under this name
Reading the filings
- Roughly $400 million and no notice on file.Form D is a notice for offerings that rely on Regulation D. A company can raise under Section 4(a)(2) instead and file nothing, or file under a holding entity with a different name. The absence is a disclosure gap for outside investors, not evidence that anything improper happened.
- The announced rounds do not quite sum to the company’s total.The six financings in the table add to $402 million, the figure CB Insights uses. The company says $404 million through the Series C. Its later releases put the total at $444 million by August 2026, according to Revenue Memo, which implies about $40 million raised in 2026 with no announcement, investors or terms.
- A new lead at every stage, with the early backers returning.General Catalyst and Andreessen Horowitz co-led the seed, Premji Invest and General Catalyst the Series A, Kleiner Perkins the Series B and Avenir Growth the Series C. The company said existing investors took at least their pro rata share in the Series B, a sign of insider conviction at a $1.64 billion price.
- Customers sit on the cap table.Memorial Hermann, Cincinnati Children’s, WellSpan Health and Universal Health Services invested alongside the venture firms. Health system investors shorten sales cycles and validate safety claims, and they also tie the company’s reference accounts to its shareholders.
- The same Kleiner partner shows up across the a16z portfolio.Mamoon Hamid of Kleiner Perkins was quoted on the Series B. He also appears as a director on both Form D filings of Ambience Healthcare, another Andreessen Horowitz company. The two firms are co-investing across healthcare AI.
- The pitch is abundance.The Grove AI release describes the combined teams as aligned around healthcare abundance. That matches the “infinite healthcare” thesis that Andreessen Horowitz published in February 2026, which argues that AI removes clinician labor as the cap on how much care can be delivered.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Scale | More than 250 million patient interactions by August 2026, up from more than 180 million in April 2026. Unaudited. | Company-stated |
| Revenue | Not disclosed. Third-party trackers estimate revenue in the mid teens of millions of dollars, which would imply a very high multiple at $3.5 billion. | Independent |
| Life sciences | Acquired Grove AI in January 2026 for clinical trial recruitment and launched a Life Sciences Division; says it is working with five of the top 20 global pharmaceutical companies. | Company-stated |
| Products | An AI agent app store for licensed clinicians (January 2025), then AI Front Door and Nurse Co-Pilot (April 2026). | Company-stated |
| Headcount | 368 employees as of September 28, 2026, by LinkedIn count. | Independent |
What to watch
- Any Form D under a holding or successor entity, which would put the cap table and offering sizes on the record for the first time.
- An announcement explaining the roughly $40 million added in 2026.
- Further acquisitions. The chief executive said in January 2026 that the company wants more deals in healthcare and life sciences this year.
- Revenue disclosure. At $3.5 billion, the valuation rests almost entirely on interaction volume and contracts that the public cannot yet price.
Related companies
Sources
- Public recordEDGAR full-text search, Form D, “Hippocratic AI” and “Hippocratic”
- CompanyHippocratic AI completes $141MM Series B financing round led by Kleiner Perkins, valuing the company at $1.64B
- CompanyHippocratic AI consolidates life sciences leadership with acquisition of Grove AI
- IndependentHippocratic AI raises $53M at a $500M valuation
- IndependentHippocratic AI scores $141M, boosting valuation to $1.64B
- IndependentHippocratic AI raises $126M Series C at a $3.5B valuation
- IndependentJPM26: Hippocratic AI acquires Grove AI
- IndependentHippocratic AI funding history
- IndependentHow Hippocratic AI makes money
Compiled from SEC records, company releases and published reports as of November 11, 2026. Form D notices report offerings under Regulation D; companies raising under other exemptions may file none. Healthcare Venture Capital Fund holds no position in Hippocratic AI. This page is not an offer to sell or a recommendation to buy any security.
